Bayer withdraws follicular lymphoma drug after further trial fails

[November 14, 2023]  FRANKFURT (Reuters) - Bayer on Monday said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market after a trial designed to confirm its benefit did not show the desired effect on overall survival.

The decision follows discussions with the U.S. Food and Drug Administration, Bayer said in a statement.

Based on a Phase II study, Aliqopa was granted accelerated approval by the FDA in 2017 for adults with follicular lymphoma whose disease had returned after at least two prior systemic therapies, but the go-ahead was contingent on further trials.

In a follow-up study the FDA had required, the addition of Aliqopa to standard immunochemotherapy did not meet the target for progression-free survival when compared to the control group in patients on standard immunochemotherapy, Bayer added.

Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay/File Photo

(Reporting by Ludwig Burger; editing by Matthias Williams)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.